|
Norethindrone Impurity 7
|
|
|
|
Norethindrone Related Compound
|
17-ethynyl-4-estrene-3,17-diol-3-acetate-17-(3'-acetoxy-2'-butenoate)
|
142154-46-9
|
|
6-Keto Norethindrone Acetate (Norethindrone Impurity G)
|
6-酮基醋酸炔諾酮
|
438244-27-0
|
|
6-beta-Hydroxy Norethindrone Acetate (Norethindrone Acetate Impurity F)
|
6-Β羥基醋酸炔諾酮
|
6856-27-5
|
|
Rivaroxaban Impurity 15
|
利伐沙班乙酰草酰胺雜質(zhì)
|
931204-39-6
|
|
Rivaroxaban Metabolite 8
|
利伐沙班代謝物8
|
|
|
6,10-di-Hydroxy Norethindrone Acetate
|
6,10-二羥基醋酸炔諾酮
|
|
|
Rivaroxaban Impurity 3
|
利伐沙班雜質(zhì)3
|
|
|
Olopatadine Carbaldehyde HCl
|
|
|
|
Norethindrone Impurity O
|
|
|
|
6,7-Didehydro Norethindrone
|
6, 7-二脫氫炔諾酮
|
31528-46-8
|
|
6-alpha-Hydroxy Norethindrone Acetate
|
6-Α羥基醋酸炔諾酮
|
6856-28-6
|
|
(S,S,R,R)-Orlistat
|
(S,S,R,R)-奧利司他
|
111466-62-7
|
|
Olopatadine Acetaldehyde
|
奧洛他定醛基雜質(zhì)
|
1376615-97-2
|
|
6-Beta-Hydroxy-19-Norandrostenedione
|
炔諾酮雜質(zhì)23(6-Β-羥基-19-去甲雄烯二酮)
|
5949-49-5
|
|
Rivaroxaban Impurity 5
|
利伐沙班雜質(zhì)5
|
|
|
Rivaroxaban Impurity 4
|
利伐沙班雜質(zhì)H
|
1429334-00-8
|
|
Ophthazin Impurity 2
|
雙肼酞嗪雜質(zhì)2
|
1044569-46-1
|
|
Rivaroxaban Impurity 12
|
利伐沙班雜質(zhì) 12
|
936232-22-3
|
|
Rivaroxaban Impurity 25
|
利伐沙班雜質(zhì)25
|
|
|
Ophthazin Sulfate
|
硫酸雙肼屈嗪
|
7327-87-9
|
|
Orlistat Impurity M1
|
奧利司他雜質(zhì)M1
|
130676-66-3
|
|
(S,R,R,R)-Orlistat
|
(S,R,R,R) -奧利司他
|
111466-61-6
|
|
Norethindrone Acetate 3-Isopropylenol Ether
|
Norethindrone Acetate 3-Isopropylenol Ether
|
|
|
Delta-5(6)-Norethindrone (Norethindrone Impurity C)
|
Δ-5(6)-NORETHINDRONE
|
22933-71-7
|
|
Orlistat Impurity 2
|
奧利司他雜質(zhì)2
|
130676-63-0
|
|
Rivaroxaban Related Compound (Ethyl 4-(3-Oxomorpholino)-Phenylcarbamate)
|
利伐沙班中間體2
|
1327778-39-1
|
|
Rivaroxaban Impurity 16
|
利伐沙班雜質(zhì) 16
|
|
|
Rivaroxaban Impurity 21
|
利伐沙班雜質(zhì) 21
|
1328136-38-4
|
|
Rivaroxaban Impurity 26
|
Rivaroxaban Impurity 26
|
1838133-00-8
|
|
Norgestrel
|
炔諾孕酮
|
6533-00-2
|
|
Norethisterone Impurity A
|
|
|
|
Rivaroxaban Related Compound
|
2-氯噻吩-5-甲酸
|
24065-33-6
|
|
N-Deformyl-N-pivaloyl Orlistat
|
N-DEFORMYL-N-PIVALOYL ORLISTAT
|
1356017-35-0
|
|
Rivaroxaban Metabolite 9
|
利伐沙班代謝物9
|
|
|
Rivaroxaban Dimer Impurity
|
|
|
|
Rivaroxaban Impurity 23
|
利伐沙班雜質(zhì)23
|
|
|
Orlistat degradation product sodium salt
|
|
|
|
Norgestrel Sulfate Sodium Salt
|
諾格瑞硫酸鹽
|
|
|
Octaverine Hydrochloride
|
辛凡林
|
6775-26-4
|
|
3-Methyl-2-quinoxalinecarboxylic acid
|
3-甲基-喹啉-2-甲酸
|
74003-63-7
|
|
Norethindrone EP Impurity F
|
炔諾酮雜質(zhì)6
|
96487-85-3
|
|
Octyl Orlistat
|
奧利司他雜質(zhì)8(奧利司他辛基)
|
1243011-56-4
|
|
(R,S,S,S)-Orlistat
|
(R,S,S,S)-奧利司他
|
104872-28-8
|
|
17,17-bis(17-hydroxy-18a-homoestr-4-ene-3-one
|
17,17-雙(17-羥基-18A-HOMOESTR-4-ENE-3-ONE
|
|
|
Rivaroxaban Impurity 1
|
利伐沙班雜質(zhì)1
|
|
|
Rivaroxaban Impurity 6
|
利伐沙班雜質(zhì)6
|
|
|
Rivaroxaban Impurity 14
|
利伐沙班相關(guān)化合物D
|
1365267-35-1
|
|
Nuzhenide Impurity 1
|
女貞子甙雜質(zhì)1
|
|
|
Rivaroxaban Impurity 13
|
利伐沙班代謝物M1
|
1160169-98-1
|
|
Rivaroxaban Impurity 29
|
Rivaroxaban Impurity 29
|
|
|
Orlistat Related Compound ((2S,3R,5S)-5-[(N-Formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic acid)
|
奧利司他開環(huán)雜質(zhì)（2S，3R，5S）異構(gòu)體
|
130793-28-1
|
|
Orlistat USP Related Compound E
|
N-甲?；?L-異亮氨酸 (1S)-1-[[(2S,3S)-3-己基-4-氧代-2-氧雜環(huán)丁基]甲基]十二烷基酯
|
1072902-75-0
|
|
Alpha-hydroxy Olopatadine Sodium Salt ( Olopatadine Impurity A)
|
阿爾法羥基奧洛他定鈉鹽(奧洛他定雜質(zhì))
|
|
|
6-beta-Hydroxy Norethindrone (Norethindrone Impurity H)
|
6-Β羥基炔諾酮
|
51724-44-8
|
|
Rivaroxaban Impurity 19
|
利伐沙班雜質(zhì) 19
|
|
|
Rivaroxaban Impurity 27
|
利伐沙班雜質(zhì)27
|
1369969-44-7
|
|
Carboxylate Ion of Nystatin
|
|
|
|
Norethindrone Acetate Dimer
|
|
|
|
N-Didesmethyl Olopatadine HCl
|
N-DidesMethyl Olopatadine HCl
|
113835-94-2
|
|
Rivaroxaban Impurity L
|
利伐沙班雜質(zhì)L
|
|
|
Olaparib Impurity 1
|
|
|
|
Rivaroxaban Impurity 24
|
利伐沙班雜質(zhì)24
|
|
|
Rivaroxaban Related Compound (R-4-(4-(5-(Aminomethyl)-2-Oxooxazolidin-3-yl)phenyl-Morpholin-3-One HCl)
|
利伐沙班相關(guān)化合物
|
1429311-47-6
|
|
Orlistat Related Compound [(S)-3-Hexyl-5,6-dihydro-6-undecyl-2H-pyran-2-one
|
奧利司他二氫吡喃酮雜質(zhì)
|
130676-64-1
|
|
6,7-Dehydro Norethindrone Acetate
|
17-羥基-19-去甲-17ALPHA-孕甾-4,6-二烯-20-炔-3-酮乙酸酯
|
106765-04-2
|
|
N-Deformyl-N-benzyloxycarbonyl Orlistat
|
N-DEFORMYL-N-BENZYLOXYCARBONYL ORLISTAT
|
108051-94-1
|
|
5-Methyl-L-Norleucine Orlistat Analogue
|
奧利司類似物
|
1356847-30-7
|
|
trans-10-Hydroxy Nortriptyline
|
-E-10-羥基去甲替林
|
74853-74-0
|
|
Delta 5(10)-Norethindrone Acetate
|
Δ5(10)醋酸炔諾酮
|
19637-28-6
|
|
Delta-5(6)-Norethindrone Acetate (Impurity C)
|
醋酸炔諾酮雜質(zhì)C
|
1175129-26-6
|
|
Norethindrone Impurity E
|
炔諾酮雜質(zhì)E
|
66964-58-7
|
|
Rivaroxaban Metabolite 5
|
利伐沙班代謝物5
|
|
|
Nortriptyline Impurity G
|
去甲替林N-氨基甲酸乙酯
|
16234-88-1
|
|
3alfa,5-beta-Tetrahydro Levonorgestrel
|
3Α,5-Β-甲氫左炔諾孕酮
|
|
|
Rivaroxaban Impurity 2
|
利伐沙班雜質(zhì)2
|
|
|
Rivaroxaban Impurity 7
|
利伐沙班雜質(zhì)7
|
|
|
Rivaroxaban Impurity G
|
利伐沙班雜質(zhì)G
|
721401-53-2
|
|
Rivaroxaban Related Compound (5-Chloro-2-Thiophenecarboxylic Acid N-Methylamide)
|
5-氯噻吩-2-甲酰甲胺
|
97799-98-9
|
|
Norethindrone 3-isopropyldienol Ether
|
|
|
|
Orlistat Impurity 3
|
奧利司他雜質(zhì)3
|
|
|
6β,17-Norethindrone Diacetate
|
|
|
|
Olopatadine N-Oxide
|
奧洛他定N氧化物
|
203188-31-2
|
|
Orlistat Dimer Impurity
|
奧利司他二聚物雜質(zhì)
|
881900-54-5
|
|
Norethindrone Impurity 2
|
炔諾酮雜質(zhì)E
|
79727-03-0
|
|
Orlistat Related Compound D
|
奧利司他相關(guān)化合物D
|
130793-27-0
|
|
Nortriptyline N-Glucuronide
|
去甲替林 N-葡糖苷酸
|
|
|
N-Desmethyl Olopatadine HCl
|
N-去甲鹽酸奧洛他定
|
|
|
Ophthazin Impurity 1
|
雙肼酞嗪雜質(zhì)1
|
|
|
Rivaroxaban Impurity 10
|
|
|
|
Rivaroxaban Impurity 11
|
利伐沙班雜質(zhì) 11
|
1411775-06-8
|
|
Rivaroxaban O-Carboxy Benzamide Impurity
|
利伐沙班雜質(zhì) 34
|
|
|
Rivaroxaban Impurity 28
|
利伐沙班雜質(zhì)28
|
2489689-18-9
|
|
Rivaroxaban Impurity 20
|
N-甲基鄰苯二甲酰亞胺
|
550-44-7
|
|
Rivaroxaban Impurity 22
|
利伐沙班雜質(zhì)22
|
|
|
Rivaroxaban Impurity 9
|
利伐沙班鄰苯二甲酰亞胺雜質(zhì)
|
446292-08-6
|
|
(S,R,S,S) Orlistat
|
(S,R,S,S) -奧利司他
|
111466-63-8
|
|
Rivaroxaban Impurity 8
|
N,N'-二[{(5S)-2-氧代-3-[4-(3-氧代-4-嗎啉基)苯基]-1,3-惡唑啉-5-基}甲基]苯基-1,2-二酰胺
|
1365267-36-2
|
|
Olaparib Impurity 2
|
奧拉帕利雜質(zhì)2
|
|
|
Nortriptyline Impurity H
|
去甲替林雜質(zhì)H
|
24755-73-5
|